ArticleHeliyon2022
Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression.
Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Admission Cytokine Profiling for ICU Mortality Prediction in Heterogeneous Acute Respiratory Failure: An Exploratory Cytokine Profiling Study.Diagnostics (Basel, Switzerland) · 2026Article
- Oxidants, antioxidants, and the clinical course of COVID-19 disease: a prospective observational study.Virology journal · 2026Observational
- Exploring blood transcriptional signatures for thrombosis diagnosis in critically ill patients with COVID-19.Blood vessels, thrombosis & hemostasis · 2026Article
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.Nature cancer · 2026Article
- Daily HIV pre-exposure prophylaxis enhances monocyte activation and reprogrammes immune cell metabolism.Frontiers in immunology · 2026Article
- Digitally Assessed Long COVID Symptomatology Is Associated With Lymphocyte Mitochondrial Dysfunction and Altered Immune Potential.Open forum infectious diseases · 2025Article
- The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.Cancers · 2024Article
- Emergency Myelopoiesis Distinguishes Multisystem Inflammatory Syndrome in Children From Pediatric Severe Coronavirus Disease 2019.The Journal of infectious diseases · 2024Article
- Early inflammatory profiles predict maximal disease severity in COVID-19: An unsupervised cluster analysis.Heliyon · 2024Article
- Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.Frontiers in immunology · 2024Review
- Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung.Frontiers in immunology · 2024Article
- Linear and non‑linear indices of vagal nerve in relation to sex and inflammation in patients with Covid‑19.Biomedical reports · 2023Article
- Low-density granulocytes display immature cells with enhanced NET formation in people living with HIV.Scientific reports · 2023Article
- Monocyte Differentiation and Heterogeneity: Inter-Subset and Interindividual Differences.International journal of molecular sciences · 2023Review
- Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic.Irish journal of medical science · 2023Article
- Characterisation of the pro-inflammatory cytokine signature in severe COVID-19.Frontiers in immunology · 2023Article
- High-dimensional comparison of monocytes and T cells in post-COVID and idiopathic pulmonary fibrosis.Frontiers in immunology · 2023Article
- Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets.Frontiers in molecular biosciences · 2023Review
- Epigenetic and transcriptomic reprogramming in monocytes of severe COVID-19 patients reflects alterations in myeloid differentiation and the influence of inflammatory cytokines.Genome medicine · 2022Article
- InvasiveDiagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
- Commented on by
Authors and funding
30 authors at 2 institutions in 1 country.
Funding
Abstract
SARS-CoV-2 infection causes a wide spectrum of disease severity. Identifying the immunological characteristics of severe disease and the risk factors for their development are important in the management of COVID-19. This study aimed to identify and rank clinical and immunological features associated with progression to severe COVID-19 in order to investigate an immunological signature of severe disease. One hundred and eight patients with positive SARS-CoV-2 PCR were recruited. Routine clinical and laboratory markers were measured, as well as myeloid and lymphoid whole-blood immunophenotyping and measurement of the pro-inflammatory cytokines IL-6 and soluble CD25. All analysis was carried out in a routine hospital diagnostic laboratory. Univariate analysis demonstrated that severe disease was most strongly associated with elevated CRP and IL-6, loss of DLA-DR expression on monocytes and CD10 expression on neutrophils. Unbiased machine learning demonstrated that these four features were strongly associated with severe disease, with an average prediction score for severe disease of 0.925. These results demonstrate that these four markers could be used to identify patients developing severe COVID-19 and allow timely delivery of therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.